Urinary Tract Infection News and Research

RSS

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.

Simple, inexpensive test quickly detects antibiotic-resistant 'superbugs'

When you get sick, you want the right treatment fast. But certain infectious microbes are experts at evading the very anti-bacterial drugs designed to fight them.

16 Oct 2018

Spurred by convenience, millennials often spurn the ‘family doctor’ model

Calvin Brown doesn’t have a primary care doctor — and the peripatetic 23-year-old doesn’t want one.

9 Oct 2018

Women who drink more water experience fewer bladder infections, study finds

In the controlled trial, women who drank an additional 1.5 liters of water daily experienced 48 percent fewer repeat bladder infections than those who drank their usual volume of fluids, said senior author Dr. Yair Lotan, Professor of Urology and with the Simmons Cancer Center at UT Southwestern.

1 Oct 2018

Study aims to investigate antimicrobial resistance of uropathogenic E. coli from elderly patients

Urinary Tract Infection is a common cause of morbidity and mortality in older adults. Escherichia coli is one of the bacterial agents with higher prevalence in community-acquired and health care associated urinary infections in elderly patients.

27 Sep 2018

Pioneering procedure for common prostate condition offered by The London Clinic

The London Clinic is one of the first hospitals in the UK to offer prostate artery embolization, a new procedure for non-cancerous enlargement of the prostate, a very common condition in older men.

24 Sep 2018

Sun Pharma receives U.S. FDA approval for CEQUA to treat patients with dry eye disease

Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

16 Aug 2018

FDA approves first oral medication for treatment of adults with Fabry disease

The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.

10 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

New guideline recommends first-trimester screening of pregnant women for asymptomatic bacteriuria

First-trimester screening of pregnant women for asymptomatic bacteriuria -- higher than normal bacteria levels without symptoms of a bladder infection -- is recommended by the Canadian Task Force on Preventive Health Care in an updated guideline in CMAJ

9 Jul 2018

CMS policy had insignificant impact on reducing healthcare-associated infections

Hospitals may have avoided financial penalties by billing hospital-associated conditions as present at the time of the patient's admission, supporting prior work that showed that a Medicare policy designed to monetarily penalize hospitals for preventable complications had an insignificant impact on reducing healthcare-associated infections.

2 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Study: Lenabasum has acceptable safety and tolerability in diffuse cutaneous systemic sclerosis

The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology, 2018, demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis with no severe or serious adverse events.

18 Jun 2018

That ‘living will’ you signed? At the ER, it could be open to interpretation.

"Don't resuscitate this patient; he has a living will," the nurse told Dr. Monica Williams-Murphy, handing her a document.

14 Jun 2018

Critical access hospitals face problems in infection prevention and control practices, shows research

Critical access hospitals face significant challenges in their infection prevention and control practices, according to new research presented at the 45th Annual Conference of the Association for Professionals in Infection Control and Epidemiology.

13 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Study: Medicaid expansion linked to reduction in ICU utilization

A new study suggests that states that expanded their Medicaid programs under the Patient Protection and Affordable Care Act (PPACA) saw a decline in ICU utilization among patients hospitalized for conditions for which hospitalizations may have been prevented through early interventions.

23 May 2018

Oral antibiotic use may increase risk of developing kidney stones, shows study

Pediatric researchers have found that children and adults treated with some oral antibiotics have a significantly higher risk of developing kidney stones.

11 May 2018

Study: One-third of bacterial infections in patients with cirrhosis induced by MDR bacteria

A worldwide study initiated to investigate the epidemiology and outcomes of bacterial infections in hospitalized patients with liver cirrhosis has reported a prevalence of multi-drug-resistant bacteria of 34% and significant regional differences in the risk of developing a multi-drug-resistant infection.

13 Apr 2018

Antibiotics could benefit women suffering from chronic bladder pain

Antibiotics can successfully help rid a patient of chronic urinary tract infection symptoms. This is the finding of a new clinical study led by Sheela Swamy of University College London in the UK.

20 Mar 2018